Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Autologous HERV-E TCR transduced T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Autologous HERV-E TCR transduced T cells||Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells||Autologous HERV-E TCR transduced T cells are patient-derived T-cells that have been engineered to express a T-cell receptor (TCR) that targets an HLA-A-A11-restricted HERV-E peptide, which potentially results in increased anti-tumor immune response against HERV-E-expressing tumor cells and increased tumor cell killing (Annals of Oncology (2018) 29 (suppl_8): viii303-viii331).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03354390||Phase I||Autologous HERV-E TCR transduced T cells||HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma||Recruiting|